生物
阿维巴坦
微生物学
抗生素
内酰胺
细菌
丝氨酸
酶
硼酸
β-内酰胺酶抑制剂
肺炎克雷伯菌
大肠杆菌
生物化学
组合化学
化学
立体化学
遗传学
基因
作者
Karen Bush,Patricia A. Bradford
标识
DOI:10.1038/s41579-019-0159-8
摘要
Resistance to β-lactam antibiotics in Gram-negative bacteria is commonly associated with production of β-lactamases, including extended-spectrum β-lactamases (ESBLs) and carbapenemases belonging to different molecular classes: those with a catalytically active serine and those with at least one active-site Zn2+ to facilitate hydrolysis. To counteract the hydrolytic activity of these enzymes, combinations of a β-lactam with a β-lactamase inhibitor (BLI) have been clinically successful. However, some β-lactam-BLI combinations have lost their effectiveness against prevalent Gram-negative pathogens that produce ESBLs, carbapenemases or multiple β-lactamases in the same organism. In this Review, descriptions are provided for medically relevant β-lactamase families and various BLI combinations that have been developed or are under development. Recently approved inhibitor combinations include the inhibitors avibactam and vaborbactam of the diazabicyclooctanone and boronic acid inhibitor classes, respectively, as new scaffolds for future inhibitor design.
科研通智能强力驱动
Strongly Powered by AbleSci AI